



This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Markers			
Integrated genomic analysis of ovarian carcinoma	An analysis of patient ovarian carcinoma samples could aid the development of new treatments and diagnostics. In 316 high-grade ovarian adenocarcinoma samples, 96% had <i>p53</i> mutations and 22% had <i>breast cancer 1 early onset (BRCA1)</i> or <i>BRCA2</i> mutations. Recurrent mutations in 7 other genes were also identified in 2%–6% of the analyzed sample cases. Next steps include analyzing additional tumor types. SciBX 4(27); doi:10.1038/scibx.2011.782 Published online July 14, 2011	Work unpatented; licensing status not applicable	The Cancer Genome Atlas Research Network. <i>Nature</i> ; published online June 29, 2011; doi:10.1038/nature10166 Contact: P.T. Spellman, Lawrence Berkeley National Laboratory, Berkeley, Calif. e-mail: spellmap@ohsu.edu